Mast Therapeutics, Inc. (NYSEMKT:MSTX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On March 23, 2017, Mast Therapeutics, Inc. (“Mast”) entered into a Sub-Sublease Agreement (the “Sub-Sublease”) with MEI Pharma, Inc. (“Sub-Sublessee”) relating to the sublease by Mast to Sub-Sublessee of approximately 13,707 square feet of rentable office space on the fifth floor of the building located at 3611 Valley Centre Drive, San Diego, California 92130 (the “Subleased Premises”).  The Subleased Premises currently serve as Mast’s corporate headquarters, but as a result of Mast’s recent corporate restructuring and its anticipated merger transaction with Savara Inc., Mast does not have an ongoing need for its current facilities.  

The term of the Sub-Sublease commences on July 1, 2017 and expires on May 31, 2020, coterminus with Mast’s sublease of the Subleased Premises to its Sublease Agreement, dated June 19, 2014, with Santarus, Inc. (“Sublessor”).  The commencement date of the Sub-Sublease may be earlier than July 1, 2017 if Sub-Sublessee completes its move-in and begins operating its business in the Subleased Premises, however, such move-in will not begin earlier than June 1, 2017.  The period beginning with the date on which the Sub-Sublease commences through May 31, 2020 is herein referred to as the “Sub-Sublease Term.”

Monthly base rent under the Sub-Sublease is $43,862.40, subject to increases of 3.0% annually on the anniversary of commencement of the Sub-Sublease Term.  However, monthly base rent for calendar month 2 of the Sub-Sublease Term shall be abated.  In addition to the base rent, Sub-Sublessee is responsible for electricity used on the Subleased Premises and, beginning on July 1, 2018 and continuing thereafter during the Sub-Sublease Term, Sub-Sublessee is obligated to pay as additional rent an amount equal to the amount of real-estate taxes and standard operating expenses associated with the Subleased Premises that are in excess of the amount of such taxes and expenses associated with the Subleased Premises for calendar year 2017.  

The Sub-Sublease contains customary default provisions allowing Mast to terminate the Sub-Sublease if Sub-Sublessee fails to cure a breach of any of its obligations within specified time periods. In addition, if Mast’s or Sublessor’s tenancy, control or right to possession of the Subleased Premises terminates by expiration of the sublease between Mast and Sublessor or the master lease or any other cause not due to the fault of Mast, the Sub-Sublease will also immediately cease and terminate.  Sub-Sublessee may not assign the Sub-Sublease or further sublet all or any part of the Subleased Premises without Mast’s prior written consent.  

The Sub-Sublease is subject to and conditioned upon the consent and waiver of Sublessor and Kilroy Realty, L.P. as master lessor to an office lease, dated October 5, 2012, with Sublessor.  If such consents and waiver are not obtained within 20 business days of March 23, 2017, either Mast or Sub-Sublessee may terminate the Sub-Sublease and Mast would be obligated to refund to Sub-Sublessee all amounts paid by Sub-Sublessee as of the date of such termination.  

A copy of the Sub-Sublease is filed as Exhibit 10.1 to this report and incorporated herein by reference. The foregoing description of the terms and conditions of the Sub-Sublease is qualified in its entirety by reference to such exhibit.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index immediately following the page of this Current Report.

About Mast Therapeutics, Inc. (NYSEMKT:MSTX)

Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company’s segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company’s AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.

Mast Therapeutics, Inc. (NYSEMKT:MSTX) Recent Trading Information

Mast Therapeutics, Inc. (NYSEMKT:MSTX) closed its last trading session down -0.002 at 0.116 with 2,136,549 shares trading hands.